MAPK9 and rheumatoid arthritis: In previous studies we have shown that levels of JNK1 and JNK2 are decreased in lymphocytes from patients with RA, and that MTX treatment results in increased levels of these signaling molecules along with a decrease in sensitivity of lymphocytes to apoptotic signals [10].